Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.

Ana Boquete-CastroGerardo Gómez-MorenoJosé Luis Calvo-GuiradoAntonio Aguilar-SalvatierraRafael Arcesio Delgado-Ruiz

Published in: Clinical oral implants research (2015)

Denosumab combined with risk factors such as dental extraction, poor oral hygiene, use of removable apparatus, and chemotherapy may favor the development of ONJ.

Keyphrases

bone mineral density
risk factors
clinical trial
giant cell
oral health
postmenopausal women
body composition
locally advanced
squamous cell carcinoma
radiation therapy
open label
phase iii
double blind